QQQ   427.02 (-0.95%)
AAPL   168.57 (-0.48%)
MSFT   412.71 (-0.45%)
META   496.39 (-0.67%)
GOOGL   155.75 (+0.87%)
AMZN   181.43 (-1.03%)
TSLA   157.32 (+0.13%)
NVDA   850.44 (-2.71%)
AMD   156.06 (-4.53%)
NIO   3.93 (+3.15%)
BABA   69.09 (-0.75%)
T   16.13 (+0.25%)
F   12.08 (-0.08%)
MU   117.29 (-3.68%)
GE   155.40 (-0.87%)
CGC   6.65 (-0.75%)
DIS   113.35 (-0.47%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.34 (-0.14%)
XOM   118.70 (+0.01%)
QQQ   427.02 (-0.95%)
AAPL   168.57 (-0.48%)
MSFT   412.71 (-0.45%)
META   496.39 (-0.67%)
GOOGL   155.75 (+0.87%)
AMZN   181.43 (-1.03%)
TSLA   157.32 (+0.13%)
NVDA   850.44 (-2.71%)
AMD   156.06 (-4.53%)
NIO   3.93 (+3.15%)
BABA   69.09 (-0.75%)
T   16.13 (+0.25%)
F   12.08 (-0.08%)
MU   117.29 (-3.68%)
GE   155.40 (-0.87%)
CGC   6.65 (-0.75%)
DIS   113.35 (-0.47%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.34 (-0.14%)
XOM   118.70 (+0.01%)
QQQ   427.02 (-0.95%)
AAPL   168.57 (-0.48%)
MSFT   412.71 (-0.45%)
META   496.39 (-0.67%)
GOOGL   155.75 (+0.87%)
AMZN   181.43 (-1.03%)
TSLA   157.32 (+0.13%)
NVDA   850.44 (-2.71%)
AMD   156.06 (-4.53%)
NIO   3.93 (+3.15%)
BABA   69.09 (-0.75%)
T   16.13 (+0.25%)
F   12.08 (-0.08%)
MU   117.29 (-3.68%)
GE   155.40 (-0.87%)
CGC   6.65 (-0.75%)
DIS   113.35 (-0.47%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.34 (-0.14%)
XOM   118.70 (+0.01%)
QQQ   427.02 (-0.95%)
AAPL   168.57 (-0.48%)
MSFT   412.71 (-0.45%)
META   496.39 (-0.67%)
GOOGL   155.75 (+0.87%)
AMZN   181.43 (-1.03%)
TSLA   157.32 (+0.13%)
NVDA   850.44 (-2.71%)
AMD   156.06 (-4.53%)
NIO   3.93 (+3.15%)
BABA   69.09 (-0.75%)
T   16.13 (+0.25%)
F   12.08 (-0.08%)
MU   117.29 (-3.68%)
GE   155.40 (-0.87%)
CGC   6.65 (-0.75%)
DIS   113.35 (-0.47%)
AMC   2.98 (+9.56%)
PFE   25.42 (-1.05%)
PYPL   63.34 (-0.14%)
XOM   118.70 (+0.01%)
NASDAQ:DARE

Daré Bioscience (DARE) Stock Price, News & Analysis

$0.30
-0.18 (-37.41%)
(As of 02:34 PM ET)
Today's Range
$0.28
$0.48
50-Day Range
$0.33
$0.57
52-Week Range
$0.27
$1.10
Volume
3.66 million shs
Average Volume
422,988 shs
Market Capitalization
$30.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Daré Bioscience MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,853.8% Upside
$6.00 Price Target
Short Interest
Healthy
0.23% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of Daré Bioscience in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.25) to $0.10 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.96 out of 5 stars

Medical Sector

563rd out of 930 stocks

Pharmaceutical Preparations Industry

263rd out of 430 stocks

DARE stock logo

About Daré Bioscience Stock (NASDAQ:DARE)

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy. The company's Phase I-ready products are DARE-VVA1, a proprietary formulation of tamoxifen for intravaginal to treat vulvar vaginal atrophy in women with hormone-receptor positive breast cancer; DARE-PDM1, a proprietary hydrogel formulation of diclofenac, a nonsteroidal anti-inflammatory drug, for vaginal administration as a treatment for dysmenorrhea; DARE-204 and DARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-GML, an intravaginally-delivered potential multi-target antimicrobial agent formulated with glycerol monolaurate; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

DARE Stock Price History

DARE Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Q4 2023 Dare Bioscience Inc Earnings Call
Madrigal Pharmaceuticals Inc.
The Press: $1,000 Dare
Remote learning day for Dare County
See More Headlines
Receive DARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/17/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DARE
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+1,932.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-30,160,000.00
Pretax Margin
-1,074.11%

Debt

Sales & Book Value

Annual Sales
$2.81 million
Book Value
($0.05) per share

Miscellaneous

Free Float
95,251,000
Market Cap
$29.69 million
Optionable
Not Optionable
Beta
1.16
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Ms. Sabrina Martucci Johnson (Age 57)
    CEO, President, Principal Financial Officer, Secretary & Director
    Comp: $804.07k
  • Ms. Lisa Walters-Hoffert (Age 65)
    Executive Officer
    Comp: $523.2k
  • Mr. Mark Walters (Age 69)
    Vice President of Operations
  • Ms. MarDee J. Haring-Layton (Age 48)
    Chief Accounting Officer
  • Dr. David Friend
    Chief Scientific Officer

DARE Stock Analysis - Frequently Asked Questions

Should I buy or sell Daré Bioscience stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DARE shares.
View DARE analyst ratings
or view top-rated stocks.

What is Daré Bioscience's stock price target for 2024?

2 brokers have issued 1 year price objectives for Daré Bioscience's shares. Their DARE share price targets range from $6.00 to $6.00. On average, they predict the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 1,853.8% from the stock's current price.
View analysts price targets for DARE
or view top-rated stocks among Wall Street analysts.

How have DARE shares performed in 2024?

Daré Bioscience's stock was trading at $0.3090 at the beginning of 2024. Since then, DARE shares have decreased by 0.6% and is now trading at $0.3071.
View the best growth stocks for 2024 here
.

Are investors shorting Daré Bioscience?

Daré Bioscience saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 235,000 shares, a decrease of 48.5% from the March 15th total of 456,200 shares. Based on an average daily volume of 385,200 shares, the short-interest ratio is currently 0.6 days.
View Daré Bioscience's Short Interest
.

When is Daré Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our DARE earnings forecast
.

How were Daré Bioscience's earnings last quarter?

Daré Bioscience, Inc. (NASDAQ:DARE) released its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.05. During the same quarter last year, the business earned ($0.24) earnings per share.

What other stocks do shareholders of Daré Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE).

How do I buy shares of Daré Bioscience?

Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DARE) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners